Investigational drug · Phase 3
Palazestrant
Also called: OP-1250
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "Palazestrant"
First trial start
2023
Nov 16, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Palazestrant", any sponsor or status.
Conditions studied
As listed on its trial records.
- Breast Cancer
- Metastatic Breast Cancer
- ER Positive Breast Cancer
- HER2 Negative Breast Carcinoma
- Locally Advanced Breast Cancer
- Advanced Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Palazestrant" as an intervention, largest first.
- Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerPivotal-lookingRecruiting
Olema Oncology, Inc.Industry
NCT07085767 · 1,000 participants (planned) · Start Nov 3, 2025 · Primary completion Dec 2028
Drug: Palazestrant; Letrozole-matching placebo and 3 more · For: Breast Cancer; Locally Advanced Breast Cancer; Metastatic Breast Cancer and 2 more
Sites: Hot Springs, Arkansas; Beverly Hills, California; La Jolla, California · 200 sites in all
- OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerPivotal-lookingActive, not recruiting
Olema Oncology, Inc.Industry
NCT06016738 · 510 participants (planned) · Start Nov 16, 2023 · Primary completion Oct 31, 2026
Drug: Palazestrant; Fulvestrant and 3 more · For: Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer and 2 more
Sites: Tucson, Arizona; Fountain Valley, California; Glendale, California · 233 sites in all
- Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast CancerActive, not recruiting
Olema Oncology, Inc.Industry
NCT05508906 · 190 participants (planned) · Start Aug 31, 2022 · Primary completion Dec 31, 2027
Drug: Palazestrant; Ribociclib and 3 more · For: Metastatic Breast Cancer; ER-positive Breast Cancer; HER2-negative Breast Cancer and 2 more
Sites: Gilbert, Arizona; San Francisco, California; Aurora, Colorado · 16 sites in all
- Phase 1 Study of OP-3136 in Advanced or Metastatic Solid TumorsPivotal-lookingRecruiting
Olema Oncology, Inc.Industry
NCT06784193 · 180 participants (planned) · Start Dec 16, 2024 · Primary completion May 30, 2027
Drug: OP-3136; Fulvestrant and 1 more · For: Advanced or Metastatic ER+ HER2- Breast Cancer (mBC); Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC); Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC) and 3 more
Sites: Gilbert, Arizona; Aurora, Colorado; Sarasota, Florida · 25 sites in all
- A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer PatientsActive, not recruiting
Olema Oncology, Inc.Industry
NCT05266105 · 60 participants · Start Dec 10, 2021 · Primary completion Mar 2026
Drug: Palazestrant; Palbociclib · For: Breast Cancer
Sites: Waratah, Australia; Westmead, Australia; South Brisbane, Australia · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- OPERA-01: a phase III study of palazestrant for ER+, HER2- advanced breast cancer after CDK4/6 inhibitor therapy.
Pistilli B, Bellet Ezquerra M, Del Mastro L, et al. · Future Oncol 2026
- Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2-ߙadvanced or metastatic breast cancer: phase 1/2 study results.
Hamilton EP, Patel MR, Borges VF, et al. · Breast Cancer Res 2025
- Discovery of Palazestrant (OP-1250), a Potent and Orally Bioavailable Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD).
Ng RA, Barratt S, Parisian A, et al. · ACS Omega 2025
- Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination.
Parisian AD, Barratt SA, Hodges-Gallagher L, et al. · Mol Cancer Ther 2024
Also in development for Breast Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- SHR-A1811Trastuzumab RezetecanPhase 327 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- RC148Phase 38 trials
RemeGen Co., Ltd. · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.